Vitalograph announced its acquisition of Morgan Scientific, a US-based respiratory diagnostics company specialising in customer-facing software for advanced pulmonary function testing (PFT) systems.
This strategic move is expected to enhance Vitalograph’s commercial presence in the US and respond to the increasing global demand for innovative respiratory diagnostic solutions.
Related: French femtech Sonio acquired by Samsung
Morgan Scientific’s flagship software, ComPAS2, powers the advanced range of PFT solutions from Vitalograph, the VitaloPFT Series.
Additionally, Morgan Scientific is Vitalograph’s pulmonary function testing solutions distributor in the US market.
Vitalograph CEO Frank Keane said: “We have a long and successful relationship with Morgan Scientific. This agreement is the natural progression for both companies as our combined expertise allows us to focus on delivering the best possible diagnostic solutions that can enable a better understanding of lung health.”
The acquisition is a pivotal step in Vitalograph’s ambitious growth strategy, aiming to triple its respiratory diagnostics business by 2026.
This aligns with the company’s mission to provide comprehensive testing solutions that support optimal respiratory healthcare on a global scale.
Morgan Scientific president Gareth Morgan said: “There is no other company in the world that we trust to uphold our legacy of innovation and to continue to put the needs of customers at the forefront of every decision.
“Joining a globally present and renowned brand such as Vitalograph will enable us to concentrate our efforts on building the business through what we know best – excellence in innovation and customer service.”
In May 2024, Morgan Scientific partnered with digital health technology innovator ZEPHYRx to integrate ZEPHYRx’s remote spirometry platform with its ComPAS2 software, enhancing the capabilities of PFT diagnostics.
